Exposure to bisphenol a correlates with early-onset prostate cancer and promotes centrosome amplification and anchorage-independent growth in vitro

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Tarapore, Pheruza ^a   Ying, Jun ^a   Ouyang, Bin ^a   Burke, Barbara ^a   Bracken, Bruce ^a   Ho, Shuk Mei ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Veteran's Hospital Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; BENZHYDRYL DERIVATIVE; ENDOCRINE DISRUPTOR; PHENOL DERIVATIVE;

ADULT; AGE; AGED; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE; CELL DISRUPTION; CELL EXPANSION; CENTROSOME; CENTROSOME AMPLIFICATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EXPOSURE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MICROTUBULE; PROSTATE CANCER; URINE LEVEL; CELL DIVISION; CHEMICALLY INDUCED; FLUORESCENT ANTIBODY TECHNIQUE; MALE; ONSET AGE; PATHOLOGY; PROSTATE TUMOR; TOXICITY; URINE;

AGE OF ONSET; BENZHYDRYL COMPOUNDS; CELL DIVISION; CENTROSOME; ENDOCRINE DISRUPTORS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; PHENOLS; PROSTATIC NEOPLASMS;

EID: 84896964170     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090332     Document Type: Article

References (72)

1. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, et al. (2004) Human prostate cancer risk factors. Cancer 101: 2371-2490. doi: 10.1002/cncr.20408. (Pubitemid 39505434)
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29. doi: 10.3322/caac.20138.
3. American Cancer Society (2013) Cancer Facts & Figures. Atlanta: American Cancer Society.
4. SEER Cancer Statistics Review (2013) 1975-2010, National Cancer Institute. Bethesda, MD. based on November 2012 SEER data submission, posted to the SEER web site.
5. Erickson BE (2008) Bisphenol A under Scrutiny. Chemical & Engineering News 86: 36-39. doi: 10.1021/cen-v086n022.p036.
6. Fiege H, Voges H-W, Hamamoto T, Umemura S, Iwata T, et al. (2002) Phenol derivatives in Ullmann's encyclopedia of industrial chemistry. Wiley-VCH, Weinheim.
7. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL (2008) Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect 116: 39-44. doi: 10.1289/ehp.10753.
8. Geens T, Aerts D, Berthot C, Bourguignon JP, Goeyens L, et al. (2012) A review of dietary and non-dietary exposure to bisphenol-A. Food Chem Toxicol 50: 3725-3740. doi: S0278-6915(12)00537-6;10.1016/j.fct.2012.07.059.
9. Keri RA, Ho SM, Hunt PA, Knudsen KE, Soto AM, et al. (2007) An evaluation of evidence for the carcinogenic activity of bisphenol A. Reprod Toxicol 24: 240-252. doi: S0890-6238(07)00195-5;10.1016/j.reprotox.2007.06.008.
10. Rogers JA, Metz L, Yong VW (2013) Review: Endocrine disrupting chemicals and immune responses: a focus on bisphenol-A and its potential mechanisms. Mol Immunol 53: 421-430. doi: S0161-5890(12)00414-2;10.1016/j.molimm.2012.09.013.
11. Ehrlich S, Williams PL, Missmer SA, Flaws JA, Ye X, et al. (2012) Urinary bisphenol A concentrations and early reproductive health outcomes among women undergoing IVF. Hum Reprod 27: 3583-3592. doi: des328;10.1093/humrep/des328.
12. Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, et al. (2008) Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 300: 1303-1310. doi:300.11.1303;10. 1001/jama.300.11.1303.
13. Donohue KM, Miller RL, Perzanowski MS, Just AC, Hoepner LA, et al. (2013) Prenatal and postnatal bisphenol A exposure and asthma development among inner-city children. J Allergy Clin Immunol 131: 736-742. doi: S0091-6749(13)00060-2;10.1016/j.jaci.2012.12.1573.
14. Duan B, Hu X, Zhao H, Qin J, Luo J (2013) The relationship between urinary bisphenol A levels and meningioma in Chinese adults. Int J Clin Oncol 18: 492-497. doi: 10.1007/s10147-012-0408-6.
15. Lingle WL, Lukasiewicz K, Salisbury JL (2005) Deregulation of the centrosome cycle and the origin of chromosomal instability in cancer. Adv Exp Med Biol 570: 393-421. doi: 10.1007/1-4020-3764-3-14. (Pubitemid 47413181)
16. Fukasawa K (2005) Centrosome amplification, chromosome instability and cancer development. Cancer Lett 230: 6-19. doi: S0304-3835(04)00988-7;10.1016/j. canlet.2004.12.028.
17. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, et al. (2010) Prioritizing genes associated with prostate cancer development. BMC Cancer 10: 599. doi:1471-2407-10-599;10.1186/1471-2407-10-599.
18. Lam YW, Yuan Y, Isaac J, Babu CV, Meller J, et al. (2010) Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells. PLoS One 5: e9075. doi: 10.1371/journal.pone.0009075.
19. Ouyang B, Bracken B, Burke B, Chung E, Liang J, et al. (2009) A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 181: 2508-2513. doi: S0022-5347(09)00280-8;10.1016/j.juro.2009.01.110.
20. Padmanabhan V, Siefert K, Ransom S, Johnson T, Pinkerton J, et al. (2008) Maternal bisphenol-A levels at delivery: a looming problem? J Perinatol 28: 258-263. doi: 7211913;10.1038/sj.jp.7211913.
21. Zhang Z, Alomirah H, Cho HS, Li YF, Liao C, et al. (2011) Urinary bisphenol A concentrations and their implications for human exposure in several Asian countries. Environ Sci Technol 45: 7044-7050. doi: 10.1021/es200976k.
22. Hornung RW, Reed LD (1990) Estimation of Average Concentration in the Presence of Nondetectable Values. Applied Occupational and Environmental Hygiene 5: 46-51. (Pubitemid 20094575)
23. WHO (1996) Biological Monitoring of Chemical Exposure in the Workplace. Occupational Health for All, Geneva: World Health Organization vol 1.
24. Mobley JA, Leav I, Zielie P, Wotkowitz C, Evans J, et al. (2003) Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro. Cancer Epidemiol Biomarkers Prev 12: 775-783. (Pubitemid 36993169)
25. Tarapore P, Hanashiro K, Fukasawa K (2012) Analysis of centrosome localization of BRCA1 and its activity in suppressing centrosomal aster formation. Cell Cycle 11: 2931-2946. doi: 21396;10.4161/cc.21396.
26. Stavnezer E, Gerhard DS, Binari RC, Balazs I (1981) Generation of transforming viruses in cultures of chicken fibroblasts infected with an avian leukosis virus. J Virol 39: 920-934. (Pubitemid 11059891)
27. Carroll PE, Okuda M, Horn HF, Biddinger P, Stambrook PJ, et al. (1999) Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18: 1935-1944. doi: 10.1038/sj.onc.1202515. (Pubitemid 29150080)
28. Delgehyr N, Sillibourne J, Bornens M (2005) Microtubule nucleation and anchoring at the centrosome are independent processes linked by ninein function. J Cell Sci 118: 1565-1575. doi: jcs.02302;10.1242/jcs.02302.
29. Ho SM, Tang WY, Belmonte de FJ, Prins GS (2006) Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 66: 5624-5632. doi: 66/11/5624;10.1158/0008-5472.CAN-06-0516.
30. Prins GS, Ye SH, Birch L, Ho SM, Kannan K (2011) Serum bisphenol A pharmacokinetics and prostate neoplastic responses following oral and subcutaneous exposures in neonatal Sprague-Dawley rats. Reprod Toxicol 31: 1-9. doi: S0890-6238(10)00306-0;10.1016/j.reprotox.2010.
31. Tang WY, Morey LM, Cheung YY, Birch L, Prins GS, et al. (2012) Neonatal exposure to estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life. Endocrinology 153: 42-55. doi: en.2011-1308;10.1210/en.2011-1308.
32. Jenkins S, Wang J, Eltoum I, Desmond R, Lamartiniere CA (2011) Chronic oral exposure to bisphenol A results in a nonmonotonic dose response in mammary carcinogenesis and metastasis in MMTV-erbB2 mice. Environ Health Perspect 119: 1604-1609. doi: 10.1289/ehp.1103850.
33. Derouiche S, Warnier M, Mariot P, Gosset P, Mauroy B, et al. (2013) Bisphenol A stimulates human prostate cancer cell migration remodelling of calcium signalling. Springerplus 2: 54. doi: 10.1186/2193-1801-2-54;93.
34. De FS, Micale RT, La MS, Izzotti A, D'Agostini F, et al. (2011) Upregulation of clusterin in prostate and DNA damage in spermatozoa from bisphenol A-treated rats and formation of DNA adducts in cultured human prostatic cells. Toxicol Sci 122: 45-51. doi: kfr096;10.1093/toxsci/kfr096.
35. Nomura H, Kawashima H, Masaki S, Hosono TY, Matsumura K, et al. (2009) Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells. Prostate Cancer Prostatic Dis 12: 375-381. doi: pcan200920;10.1038/pcan. 2009.20.
36. Hess-Wilson JK, Webb SL, Daly HK, Leung YK, Boldison J, et al. (2007) Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. Environ Health Perspect 115: 1646-1653. doi: 10.1289/ehp.10283.
37. Carwile JL, Michels KB (2011) Urinary bisphenol A and obesity: NHANES 2003-2006. Environ Res 111: 825-830. doi: S0013-9351(11)00143-5;10.1016/j. envres.2011.05.014.
38. Ye X, Wong LY, Bishop AM, Calafat AM (2011) Variability of urinary concentrations of bisphenol A in spot samples, first morning voids, and 24-hour collections. Environ Health Perspect 119: 983-988. doi: 10.1289/ehp.1002701.
39. Volkel W, Colnot T, Csanady GA, Filser JG, Dekant W (2002) Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chem Res Toxicol 15: 1281-1287. doi: tx025548t.
40. Dekant W, Volkel W (2008) Human exposure to bisphenol A by biomonitoring: methods, results and assessment of environmental exposures. Toxicol Appl Pharmacol 228: 114-134. doi: S0041-008X(07)00561-3;10.1016/j.taap.2007.12.008.
41. Mahalingaiah S, Meeker JD, Pearson KR, Calafat AM, Ye X, et al. (2008) Temporal variability and predictors of urinary bisphenol A concentrations in men and women. Environ Health Perspect 116: 173-178. doi: 10.1289/ehp.10605. (Pubitemid 351356722)
42. Townsend MK, Franke AA, Li X, Hu FB, Eliassen AH (2013) Within-person reproducibility of urinary bisphenol A and phthalate metabolites over a 1 to 3 year period among women in the Nurses' Health Studies: a prospective cohort study. Environ Health 12: 80. doi: 1476-069X-12-80;10.1186/1476-069X-12-80.
43. CL, Ho SM (2012) Developmental reprogramming of cancer susceptibility. Nat Rev Cancer 12: 479-486. doi: nrc3220;10.1038/nrc3220.
44. Prins GS, Tang WY, Belmonte J, Ho SM (2008) Developmental exposure to bisphenol A increases prostate cancer susceptibility in adult rats: epigenetic mode of action is implicated. Fertil Steril 89: e41. doi: S0015-0282(07)04305- 1;10.1016/j.fertnstert.2007.12.023.
45. Morgentaler A, Rhoden EL (2006) Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 68: 1263-1267. doi: S0090-4295(06)01962-5;10.1016/j.urology.2006.08. 1058.
46. Rhoden EL, Riedner CE, Morgentaler A (2008) The ratio of serum testosteroneto-prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol 179: 1741-1744. doi: S0022-5347(08)00051-7;10.1016/j.juro.2008.01. 045.
47. Guay AT, Perez JB, Fitaihi WA, Vereb M (2000) Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocr Pract 6: 132-138. doi: ep99055.or.
48. Xi W, Lee CK, Yeung WS, Giesy JP, Wong MH, et al. (2011) Effect of perinatal and postnatal bisphenol A exposure to the regulatory circuits at the hypothalamus-pituitary-gonadal axis of CD-1 mice. Reprod Toxicol 31: 409-417. doi: S0890-6238(10)00353-9;10.1016/j.reprotox.2010.12.002.
49. Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, et al. (2000) Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol 16: 1091-1097.
50. Brownlee CW, Rogers GC (2013) Show me your license, please: deregulation of centriole duplication mechanisms that promote amplification. Cell Mol Life Sci 70: 1021-1034. doi: 10.1007/s00018-012-1102-6.
51. Avidor-Reiss T, Gopalakrishnan J (2013) Building a centriole. Curr Opin Cell Biol 25: 72-77. doi: S0955-0674(12)00180-9;10.1016/j.ceb.2012.10.016.
52. Lee HH, Zhu Y, Govindasamy KM, Gopalan G (2008) Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells. Endocr Relat Cancer 15: 765-775. doi: ERC-07-0213;10.1677/ERC-07-0213.
53. Sheng ZG, Tang Y, Liu YX, Yuan Y, Zhao BQ, et al. (2012) Low concentrations of bisphenol a suppress thyroid hormone receptor transcription through a nongenomic mechanism. Toxicol Appl Pharmacol 259: 133-142. doi:S0041-008X(11)00475-3;10.1016/j.taap.2011.12.018.
54. Qin XY, Kojima Y, Mizuno K, Ueoka K, Muroya K, et al. (2012) Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One 7: e36711. doi: 10.1371/journal.pone.0036711;PONE-D-12-06650.
55. Watson CS, Bulayeva NN, Wozniak AL, Finnerty CC (2005) Signaling from the membrane via membrane estrogen receptor-alpha: estrogens, xenoestrogens, and phytoestrogens. Steroids 70: 364-371. doi: S0039-128X(05)00075-9;10.1016/j. steroids.2005.03.002.
56. Safe SH, Pallaroni L, Yoon K, Gaido K, Ross S, et al. (2002) Problems for risk assessment of endocrine-active estrogenic compounds. Environ Health Perspect 110 Suppl 6: 925-929. doi: sc271-5-1835.
57. Thomas P, Dong J (2006) Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol 102: 175-179. doi: S0960-0760(06)00262-7;10.1016/j.jsbmb.2006.09.017.
58. Matsushima A, Teramoto T, Okada H, Liu X, Tokunaga T, et al. (2008) ERRgamma tethers strongly bisphenol A and 4-alpha-cumylphenol in an induced-fit manner. Biochem Biophys Res Commun 373: 408-413. doi: S0006-291X(08)01180-7;10. 1016/j.bbrc.2008.06.050.
59. Okada H, Tokunaga T, Liu X, Takayanagi S, Matsushima A, et al. (2008) Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-gamma. Environ Health Perspect 116: 32-38. doi: 10.1289/ehp.10587.
60. De CS, van LN (2012) Endocrine-disrupting chemicals: associated disorders and mechanisms of action. J Environ Public Health 2012: 713696. doi: 10.1155/2012/713696.
61. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, et al. (2011) Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 71: 6019-6029. doi: 0008-5472.CAN-11-1417;10.1158/0008-5472.CAN-11-1417.
62. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, et al. (2010) Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70: 7992-8002. doi: 0008-5472.CAN-10-0585;10.1158/0008-5472. CAN-10-0585.
63. Balk SP, Knudsen KE (2008) AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6: e001. doi: 10.1621/nrs.06001.
64. Lehmann L, Metzler M (2004) Bisphenol A and its methylated congeners inhibit growth and interfere with microtubules in human fibroblasts in vitro. Chem Biol Interact 147: 273-285. doi: 10.1016/j.cbi.2004.01. 005;S0009279704000079. (Pubitemid 38591497)
65. George O, Bryant BK, Chinnasamy R, Corona C, Arterburn JB, et al. (2008) Bisphenol A directly targets tubulin to disrupt spindle organization in embryonic and somatic cells. ACS Chem Biol 3: 167-179. doi: 10.1021/cb700210u.
66. Pfeiffer E, Rosenberg B, Deuschel S, Metzler M (1997) Interference with microtubules and induction of micronuclei in vitro by various bisphenols. Mutat Res 390: 21-31. doi: S0165-1218(96)00161-9.
67. Korzeniewski N, Hohenfellner M, Duensing S (2013) The centrosome as potential target for cancer therapy and prevention. Expert Opin Ther Targets 17: 43-52. doi: 10.1517/14728222.2013.731396.
68. Cheung CH, Coumar MS, Chang JY, Hsieh HP (2011) Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Pat 21: 857-884. doi: 10.1517/13543776.2011.574614.
69. Schoffski P (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14: 559-570. doi: theoncologist. 2009-0010;10.1634/theoncologist.2009-0010.
70. Ling H, Peng L, Seto E, Fukasawa K (2012) Suppression of centrosome duplication and amplification by deacetylases. Cell Cycle 11: 3779-3791. doi:21985;10.4161/cc.21985.
71. Chan JY (2011) A clinical overview of centrosome amplification in human cancers. Int J Biol Sci 7: 1122-1144.
72. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, et al. (2014) EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol 65: 467-479. doi: S0302-2838(13)01199-8;10.1016/j.eururo.2013.11.002.